| Name | N-Cyclohexyl-2-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-2-methoxyphenyl]imidazo[1,2-a]pyrazin-3-amine |
|---|---|
| Synonyms |
N-Cyclohexyl-2-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-2-methoxyphenyl]imidazo[1,2-a]pyrazin-3-amine
Imidazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[4-(3,5-dimethyl-4-isoxazolyl)-2-methoxyphenyl]- |
| Description | A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation; dramatically reversed HIV-1 latency at both low (2.5 uM) and high (5 uM) doses in multiple cell models of HIV-1 latency through promoting Tat-dependent transcriptional elongation and Tat-P-TEFb association; enhances the latency-reversing effects of PKC agonists (prostratin, bryostatin-1) in CD8-depleted PBMCs containing latent viral reservoirs. |
|---|---|
| References | References 1. Huang H, et al. Front Microbiol. 2017 Jun 7;8:1035. View Related Products by Target Bromodomain |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C24H27N5O2 |
| Molecular Weight | 417.504 |
| Exact Mass | 417.216461 |
| LogP | 3.83 |
| Index of Refraction | 1.675 |